| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8681211 | Brain and Development | 2018 | 6 Pages |
Abstract
Our case reinforces the role of KD as a novel therapeutic option for ATP1A3-related conditions. However, proper dedicated confirmatory trials on KD are necessary.
Related Topics
Life Sciences
Neuroscience
Developmental Neuroscience
Authors
Tommaso Schirinzi, Federica Graziola, Raffaella Cusmai, Lucia Fusco, Francesco Nicita, Mirella Elia, Lorena Travaglini, Enrico Bertini, Paolo Curatolo, Federico Vigevano, Alessandro Capuano,